## **ATTACHMENT 2**

# UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

IN RE: NEW ENGLAND COMPOUNDING PHARMACY, INC. PRODUCTS LIABILITY LITIGATION

MDL No. 2419

Master Dkt.: 1:13-md-02419-FDS

THIS DOCUMENT RELATES TO:

All Actions

THE PLAINTIFFS' STEERING COMMITTEE'S CONSOLIDATED RESPONSE TO SUBPOENA OBJECTIONS

### TABLE OF CONTENTS

INTRO	ODUCT	TON	1
BACK	GROU	ND	3
ACCO	OMMOI	DATIONS	4
	A.	The PSC will narrow the scope of the documents and information requested.	5
	B.	The PSC will give objectors who agree to produce documents on a rolling basis until August 15, 2013 to complete their production	7
	C.	The PSC will forgo record keeper depositions, barring extenuating circumstances.	7
LEGA	L STA	NDARD	7
RESPO	RESPONSES TO OBJECTIONS		8
I.	BURD	EN (I.E., TIME AND EXPENSE) OBJECTIONS	8
	A.	The request for production of documents is neither overly broad nor unduly burdensome; nevertheless, the PSC will cut back the scope of some requests	8
	В.	The requested documents are relevant and are reasonably calculated to lead to the discovery of admissible evidence	9
	C.	The time periods given by the Accommodations are reasonable	10
	D.	Most subpoenaed information cannot be obtained from public sources or from NECC.	11
II.	JURISDICTIONAL AND PROCEDURAL OBJECTIONS		12
	E.	This Court has jurisdiction to centrally enforce the subpoenas.	12
	F.	Plaintiffs may take discovery of nonparties.	14
	G.	To the extent that the Court's orders limited the subpoenas' contents, the subpoenas comply with those Orders	16
	H.	The subpoenas do not intentionally seek any privileged communications between attorneys and their clients	17
	I.	If the PSC takes depositions pursuant to the subpoena, the attendance fee will be paid	17

## Cease 1:13740 02499405 Poolument 37252 Fille 099199133 Pages 49856

	J.	Plaintiffs may seek discovery of parties through either Rule 45 or Rule 34	18
	K.	The subpoenas were served in compliance with the Federal Rules	19
	L.	By definition, the subpoenas are limited to information in the recipient's possess, custody, or control	20
	M.	The time to respond proposed in the Accommodations is reasonable.	20
	N.	Parties to the MDL knew subpoenas were going out to clinics and received copies of the subpoenas actually issued	21
III.	CON	FIDENTIALITY OBJECTIONS	22
	O.	The Protective Order will protect confidential information.	22
	P.	The Court's Orders, the selected vendor, and the process provided for producing protected health information comply with HIPAA	22
IV.	MOT	IVE OBJECTIONS	25
	Q.	The PSC is doing its job, not trolling for clients	25
CON	CLUSI	ON	26

### TABLE OF AUTHORITIES

CASES	Page(s)
Adams v. Dolgencorp, LLC, Case No. 11-784, 2012 U.S. Dist. LEXIS 71066 (M.D. La. May 22, 2012)	17
Bare v. Brand Energy & Infrastructure Servs., Case No. 09-807 2012 U.S. Dist. LEXIS 153881 (D. Utah October 24, 2012)	21
Commonwealth Care Alliance v. Astrazeneca Pharmaceuticals L.P., 05-0269-BLS, Dkt. No. 169 (Suffolk Sup. Dec. 20, 2012)	23
Commonwealth of Virginia v. McKesson Corporation, 11-02782-SI, Dkt. No. 31 (N.D. Cal. Dec. 12, 2011)	23
Cont'l Datalabel, Inc. v. Avery Dennison Corp., 2010 U.S. Dist. LEXIS 68703 (D. Mass. June 15, 2010)	9
Covey Oil Co. v. Continental Oil Co., 340 F.2d 993 (10th Cir. 1965)	12
Doe v. Hersemann, 155 F.R.D. 630 (N.D. Ind. 1994)	19
First City, Texas-Houston, N.A. v. Rafidain Bank, 197 F.R.D. 250 (S.D.N.Y. 2000),	18
Government Employees Hosp. Ass'n v. Serono Int', l S.A., 05-cv-11935-PBS, Dkt. No. 109 (D. Mass. July 13, 2007)	23
Grider v. Keystone Health Plan Cent., Inc., 2005-MC-40, 2005 U.S. Dist. LEXIS 44069, 2005 WL 2030456 (M.D. Pa. July 28, 2005)	15
Hall v. Sullivan, 229 F.R.D. 501 (D. Md. 2005)	19
HCA, Inc. v. U.S. ex. Rel. Pogue, 2002 WL 31953748 (D. Tn. 2002)	14
Heidelberg Ams., Inc. v. Tokyo Kikai Seisakusho, Ltd., 333 F.3d 38 (1st Cir. 2003)	8
Hendricks v. Total Quality Logistics, LLC, 275 F.R.D. 251 (S.D. Ohio 2011)	21

In re Actiq Sales and Mktg. Practices Litig., 07-cv-04492-PBT, Dkt. No. 293 (E.D. Penn. Sept. 7, 2011)	23
In Re Artra Group, Ltd., Case No. 02-A 01086	24
In re Bextra and Celebrex Marketing, Sales Practices and Prod. Liab. Litig., 05-CV-01699-CRB, Dkt. No. 2595 (N.D. Cal. Dec. 8, 2008)	23, 13
In Re Christian Brothers Institute, Case No. 11-22820 (RDD)	24
In re Clients & Former Clients of Baron & Budd, P.C., 478 F.3d 670 (5th Cir. 2007)	13
In Re Downey Regional Medical Center, Case No. 2:09-bk-34714-SB	24
In re Neurontin Mktg., 245 F.R.D. 55, 58 (D. Mass. 2007)	14, 13
In re Online DVD Rental Antitrust Litig., 744 F. Supp. 2d 1378 (J.P.M.L. 2010)	14
In Re Owens Corning, LLC, Case No. 00-03837 (JKF)	24
In re Pharmaceutical Industry Average Wholesale Price Litig., 01-CV-12257-PBS, Dkt. No. 5455 (D. Mass. July 21, 2008)	23
In re Pharmaceutical Industry Average Wholesale Price Litig., 01-CV-12257-PBS, Dkt. No. 865 (D. Mass. June 8, 2004)	23
In re Relafen Antitrust Litig. v. Smithkline Beecham Corp., 2004 U.S. Dist. LEXIS 29834 (D. Mass. Nov. 24, 2004)	23
In re Subpoena Duces Tecum, Case No. 3:12-mc-0078, 2012 U.S. Dist. LEXIS 175871 (M.D. Tenn. December 10, 2012)	19
In re Subpoena Issued to Boies, Schiller & Flexner LLP, 2003 WL 1831426 (D.N.Y. 2003)	14
In re Subpoenas Served on Wilmer, Cutler & Pickering & Goodwin Proctor LLP, 255 F.Supp.2d 1 (D.D.C. 2003)	13
In re Tricor Indirect Purchaser Antitrust Litig., 05-cv-00360-SLR, Dkt. No. 510 (D. Del. May 8, 2009)	23

## Cease 1:13740 02499405 Produment 37252 Fille 099199133 Page 6 70956

In re Tricor Indirect Purchaser Antitrust Litig., 05-cv-00360-SLR, Dkt. No. 558 (D. Del. Feb. 2, 2010)	23
In re U.S. Office Prod. Co. Sec. Litig., 251 F.Supp.2d 58 (D.D.C. 2003)	13
In re Visa Check/Mastermoney Antitrust Litig., 2002 U.S. Dist. LEXIS 23327 (E.D.N.Y. June 21, 2002)	23
In Re W.R. Grace, Case No. 01-01139 (JFK)	24
King v. Crown Plastering Corp., 170 F.R.D. 355 (E.D.N.Y. 1997)	19
Linke Enterprises of Oregon, Inc. v. Champion Lab. Inc., Case No. 90-544, 1991 U.S. Dist. LEXIS 7155 (D. Ore. May 20, 1991)	20
Lowe v. Vadlamudi, Case No. 08-10269, 2012 U.S. Dist. LEXIS 127586 (E.D. Mich. Sept. 7, 2012)	20
Mann v. Univ. of Cincinnati, 114 F.3d 1188, Nos. 95-3195, 95-3292, (6th Cir. May 27, 1997)	20
Mortgage Information Services v. Kitchens, 210 F.R.D. 562 (W.D.N.C. 2002)	18
Myers v. Amisub (SFH), Inc., 382 S.W.3d 300 (Tenn. 2012)	6, 7
New England Carpenters Health Benefits Fund v. First Databank, Inc., 05-cv-11148-PBS, Dkt. No. 139 (D. Mass. 2006)	23
Sanchez-Medina v. Unicco Serv. Co., 265 F.R.D. 29 (D.P.R. 2010)	10
SEC v. Rex Venture Group, LLC, Case No. 5:13-MC-004, 2013 U.S. Dist. LEXIS 44564 (M.D. Fla. March 28, 2013)	19
Sham v. Hyannis Heritage House Hotel, Inc., 118 F.R.D. 24 (D. Mass. 1987)	15
Steel Works Rebar Fabricators, LLC v. Alterra Am. Ins. Co., Case No. 11-24032, 2012 U.S. Dist. LEXIS 72985 (S.D. Fla. May 25, 2012)	21
Thomas v. Rockin D Marine Servs., LLC, Case No. 12-1315, 2013 U.S. Dist. LEXIS 60007 (E.D. La. April 25, 2013)	20

TracFone Wireless, Inc. v. Technopark Co., Ltd., 281 F.R.D. 683 (S.D. Fla.)	19
Ultradent Prods., Inc. v. Hayman, 2002 U.S. Dist. LEXIS 18000, 2002 WL 31119425 (S.D.N.Y.2002)	19
United States EPA v. GE, 197 F.3d 592 (2d Cir. 1999)	20
Visx, Inc. v. Nidek Co., 208 F.R.D. 615 (N.D. Cal. 2002)	13
Western Res., Inc. v. Union Pac. R.R., 2002 U.S. Dist. LEXIS 14897 (D. Kan.2002)	19
STATUTES	
28 U.S.C. 1407(b)	13
Tenn. Code Ann. § 29-26-121	6
OTHER AUTHORITIES	
9 Moore's Federal Practice § 45.03[1]	18
Wright and Miller, FEDERAL PRACTICE AND PROCEDURE, §2463.1 (2008 ed.)	12, 13
Fed.R.Civ.P. 26(b)(3)	9, 10, 15
Fed.R.Civ.P. 30	13
Fed.R.Civ.P. 34	14, 19
Fed.R.Civ.P. 45	. passim
Malani A.N., Magnetic Resonance Imaging Screening to Identify Spinal and Paraspinal Infections Associated with Injections of Contaminated Methylprednisolone Acetate, JAMA 309(23):2465-2472 (June 19, 2013)	15
Morbidity and Mortality Weekly Report, 62(19)	15
Radiology: MRI May Spot Meningitis from Tainted Steroids	15

#### INTRODUCTION

The Plaintiffs' Steering Committee ("PSC") has served subpoenas on 85 clinics, doctors, and/or healthcare providers ("subpoena recipients"). The PSC needs this information to (1) bolster its liability case against NECC, (2) to understand the role clinics, doctors, and/or health care providers played in the unfolding of the NECC-related debacle (including whether they or others share any liability) and (3) provide actual notice of any bar date to tort victims. The PSC shared these goals with the Court, defendants, the Chapter 11 Trustee, the Creditors' Committee, other plaintiffs' counsel, and – frankly – anyone who would listen for months before the subpoenas actually went out. The PSC sought to put procedures in place to deal with potentially thorny issues *before* the subpoenas were served. The Court, fully apprised of the PSC's plan, granted the PSC's motions to partially lift the discovery stay, entered a protective order addressing confidentiality, entered a qualified protective order addressing the production of protected health information, agreed to enforce all subpoenas centrally, and even (for the second time) explicitly authorized the PSC to issue subpoenas seeking the information requested in thae attachment to the subpoenas.

Despite all of this groundwork, 31 subpoena recipients have filed objections with the Court ("objectors").<sup>2</sup> Many of those pleadings address issues this Court has already grappled with and decided. And many pleadings raise similar objections. This consolidated response is

<sup>&</sup>lt;sup>1</sup> See Exhibit A, list of all subpoenaed clinics, doctors, and/or health care providers. The PSC has also served other entities outside of this category; those objections will be addressed separately.

<sup>&</sup>lt;sup>2</sup> See Exhibit B, list of all filed objections and motions to quash, identifying arguments raised by each filer (presented in the order addressed in this response).

an effort to identify and address common substantive objections in a single cross-cutting pleading.<sup>3</sup>

The objections largely fall into four camps: (1) objections to the burden (*i.e.*, time and expense) required to comply with the subpoena, (2) procedural objections, (3) confidentiality objections, and (4) motive objections. Exhibit C lists all filed objections and identifies the arguments made in each.

Many objectors objected based on burden; few (if any) provided estimates of the time or expenses likely to be incurred in responding. Nevertheless, the Plaintiffs' Steering Committee has taken another long, hard look at deposition notices and the documents requested. And – in an effort to be responsive to recipients' concerns about burden while still zealously representing victims – the Plaintiffs' Steering Committee will cut back the scope of the requested documents as described in the "Accommodations" section below and in the attached, redlined, amended Exhibit B. The PSC will also forgo all noticed depositions (barring exceptional circumstances) and give objectors who agree to a rolling production until the close of discovery (August 15, 2013) to complete production of documents.

None of the objections make a compelling case for modifying or quashing the subpoenas. There may have been a few technical procedural flaws in the service of a few subpoenas – it is probably inevitable given the number – but all can be easily remedied. Many objections belie a lack of familiarity with the now common practice of producing names and contact information of victims in a manner compliant with HIPAA for the purposes of providing notice in class actions and bankruptcies. And the argument that the PSC is seeking discovery in order to drum up new clients, particularly since the qualified protective order bars the PSC from accessing patient

<sup>&</sup>lt;sup>3</sup> Some objections raise objections or issues that are specific to a particular subpoena recipient. The Plaintiffs' Steering Committee has or will (today) file additional responses to address those objections.

information, is barely worth dignifying with a response. The Court should deny the objections and motions to quash in their entirety.

#### **BACKGROUND**

On June 21, 2013, the Court entered an Order on Central Enforcement of Subpoenas ("Order on Central Enforcement") and an Order Granting Plaintiffs Leave to Serve Subpoenas and Qualified Protective Order Regarding Protection of Health Information ("Qualified Protective Order").<sup>4</sup>

On or about June 21, 2013, and pursuant to the Order on Central Enforcement and the Qualified Protective Order, attorneys acting on behalf of the Plaintiffs' Steering Committee served subpoenas on clinics identified by the United States Centers for Disease Control and Prevention ("CDC") (the "Identified Clinics") as having received medication from any of three recalled lots of Methylprednisolone Acetate ("MPA") from New England Compounding Pharmacy, Inc. ("NECC"). The subpoenas contained both a Notice of Deposition (to take the deposition of a designated Records Custodian) and a demand for production of certain documents identified in the subpoena. The subpoenas were served substantially in the form of the sample attached hereto as Exhibit C.<sup>5</sup> A small number of subpoenas were served on additional clinics as the PSC became aware of patients who received notice that they had been exposed to contaminated NECC medication by and from clinics that were not among the CDC's Identified Clinics. Exhibit A identifies all subpoenaed clinics.

<sup>&</sup>lt;sup>4</sup> Dkt. Nos. 193, 192.

<sup>&</sup>lt;sup>5</sup> Some subpoenas served on clinics in the State of Tennessee contained additional requirements in the request for production of document due to unique circumstances arising from the statutory environment in that state.

Several subpoena recipients have filed objections to, or motions to quash, the subpoenas.

Others raised objections informally with plaintiffs' counsel. Most objections to the subpoenas, and alleged grounds for quashing, are repeated among the many objections and motions to quash.

On June 28, 2013 the Chapter 11 Trustee filed his Motion for an Order (I) Establishing Bar Dates for Filing Proofs of Claim; (II) Approving Certain Additional Documentation Requirements and Procedures for Personal Injury Tort and Wrongful Death Claims; (III) Approving the Form and Manner of Notice Thereof; and (IV) Granting Additional Related Relief. U.S. Bankruptcy Court, D. Mass., Case No.: 12-19882-HJB, Dkt. No. 263 ("Bar Date Motion"). In his Bar Date Motion the Trustee seeks to establish a date by which all claims, including claims for personal injury and wrongful death, must be filed in the Bankruptcy Court, and to establish a protocol for giving notice of such bar date and filing requirements to all prospective claimants. The method of identifying and giving notice to all prospective claimants is a central issue in the Trustee's Bar Date Motion.<sup>6</sup>

#### ACCOMMODATIONS

The PSC spent an inordinate amount of time crafting the requests attached to the subpoenas. At the time the subpoenas issued, the PSC firmly believed that the information requested was the bare minimum we could ask for given the unusual circumstances of this case.

Since issuing the subpoenas, the PSC has met and deliberated further – both internally and with subpoena recipients – in an effort to further minimize the burden on clinics and reach accommodation with the clinics on many of the objections. The PSC's deliberations resulted in a determination to make three significant accommodations to address the clinics' concerns: (i) the production of documents required pursuant to the subpoenas would be significantly reduced, (ii)

<sup>&</sup>lt;sup>6</sup> The deadline to respond or object to the Trustee's Motion for Bar Date has been extended to July 22, 2013; a hearing on the motion will be held on July 24 in Springfield, MA. (12-19882, Dkt. No. 307).

"Records Custodian" depositions will only be taken in cases in which unique circumstances require a deposition, such as the failure of a particular clinic to cooperate in the production of documents pursuant to subpoena, and (iii) the deadline for producing documents would be extended to August 15, 2013 for those objectors who agreed to produce documents on a rolling basis (collectively, the "Accommodations").

Plaintiffs' counsel relayed these accommodations piecemeal to some, but not all, subpoena recipients. It appear that very few, if any, subpoena recipients considered these proposed accommodations before filing objections (in part, because they may not have been aware of the proposed accommodations before their filing).

#### A. The PSC will narrow the scope of the documents and information requested.

The narrower scope of document production required pursuant to subpoena is described in the Memorandum attached hereto as Exhibit C.<sup>7</sup> Among other things, these modifications limit requests to the four products the CDC identified as contaminated and (as a practical matter) restrict the time period to 2012.

Unless otherwise noted, all requests are limited in scope to the two years before October 6, 2012. In particular, requests relating to the contaminated lots are even narrower, as all lots were produced in 2012.

Requests 1, 3, and 4, originally requesting information relating to the procurement from NECC of "MPA and any other injectable steroid preparations" (Request 1), "cardioplegic solution" (Request 3) and ophthalmic solution (Request 4) will be satisfied by producing

<sup>7</sup> The PSC reserves the right to require the production of additional documents in the future, pursuant to the original document requests, should circumstances develop that necessitate producing the requested information.

responsive information relating to the four products the CDC has identified as contaminated: MPA, Triamcinolone, Cardioplegia solution, and Betamethasone from specified lots.<sup>8</sup>

Request 2 is limited to information relating to equivalents to MPA that the clinics obtained from other compounders or manufacturers since January 1, 2012. But it is clarified also include the same information relating to equivalents the clinics obtained for Triamcinolone, Cardioplegia solution, and Betamethasone.

Request 5 is withdrawn as to all clinics; but the PSC reserves the right to request this information from particular clinics based on facts relating to specific plaintiffs.

Request 6 is limited to lists of patients who received an injection of a medication lot that the CDC has determined was contaminated AND to any lists of patients already compiled by a clinic in response to a request from any Federal or State agency, any Grand Jury Subpoena, or any other governmental entity.

Request 9 is limited to the NECC products determined by the CDC to be contaminated.

Request 11 is withdrawn.

Request 17 is limited to responsive documents that provide coverage for the use of any NECC products identified as contaminated by the CDC.

Requests 19, 20, and 21 are withdrawn, except as to clinics in Tennessee.<sup>9</sup>

\_

<sup>&</sup>lt;sup>8</sup> http://emergency.cdc.gov/HAN/han00337.asp.

<sup>&</sup>lt;sup>9</sup> The PSC understands that some state law pleading requirements necessitate that plaintiffs' possess this information. For example, under the Tennessee Medical Malpractice Act (the "TMMA"), at least sixty days prior to filing suit, each defendant named in a medical malpractice case must be given pre-suit notice identifying, amongst other information, all defendants named in the suit and must be provided with a HIPAA-compliant medical release. Tenn. Code Ann. § 29-26-121. Failure to follow these requirements subjects a claim to dismissal. *See Myers v. Amisub (SFH), Inc.*, 382 S.W.3d 300 (Tenn. 2012) (discussing requirements). Accordingly, and to the extent that a plaintiff in this MDL needs to seek recovery under the TMMA, it is absolutely necessary to know the identity and address of all potential defendants prior to filing suit or a plaintiff runs the risk of not being made whole.

B. The PSC will give objectors who agree to produce documents on a rolling basis until August 15, 2013 to complete their production.

The PSC will agree that subpoena recipients who commit to producing responsive materials on a rolling basis may have until August 15, 2013 to complete production. August 15, 2013 is the deadline for discovery set by the Case Management Order.

C. The PSC will forgo record keeper depositions, barring extenuating circumstances.

The subpoenas were served with a notice of deposition for a "keeper of the record" deposition. The PSC will forgo taking records custodian depositions unless unique circumstances require the deposition to take place. As of now, the only depositions going forward are in Tennessee.

#### LEGAL STANDARD

A court must quash or modify a subpoena only if it fails to allow a reasonable time to comply, require travel of more than 100 miles from home, requires disclosure of privileged or other protected matter, if no exception or waiver applies, or subjects a person to undue burden.<sup>11</sup>

A court may exercise its discretion to quash or modify a subpoena if it requires disclosing a trade secret of other confidential commercial information, disclosing an unretained expert's opinion, or requires a nonparty to incur substantial expense to travel more than 100 miles to attend trial.<sup>12</sup>

<sup>&</sup>lt;sup>10</sup> So far, the only depositions the PSC intends to conduct are in Tennessee. Unique features of Tennessee law, discussed in the previous footnote and more further explained in *Myers*, 382 S.W.3d 300, require that these depositions go forward. All Tennessee clinics served with a subpoena, with limited exceptions, have filed objections with this Court, and as a result the noticed depositions have been postponed pending a ruling by this Court on the outstanding objections.

<sup>&</sup>lt;sup>11</sup> Fed.R.Civ.P. 45(c)(3)(A).

<sup>&</sup>lt;sup>12</sup> Fed.R.Civ.P. 45(c)(3)(B).

#### RESPONSES TO OBJECTIONS<sup>13</sup>

#### I. BURDEN (I.E., TIME AND EXPENSE) OBJECTIONS

A. The request for production of documents is neither overly broad nor unduly burdensome; nevertheless, the PSC will cut back the scope of some requests.

**Objection:** The request for production of documents is overly broad and unduly burdensome. <sup>14</sup>

**Response:** Many clinics claimed that responding to the subpoenas would be burdensome. It is, undoubtedly, a burden to have to respond to a subpoena. But the question, according to Federal Rule of Civil Procedure 45(c)(3)(A)(iv), is whether it is an "undue" burden. At bottom, as the First Circuit put it, the central question is whether the party's need for the information overcomes the nonparties' rationale for resisting disclosure. <sup>15</sup>

Here, the PSC needs this information (1) to establish or bolster its liability case against NECC, (2) to understand the role clinics, doctors, and/or health care providers played in the unfolding of the NECC-related debacle (including whether they or others share any liability) and (3) for purposes of providing actual notice of the bar date to potential claimants.

None of the objectors offer any rationale for resisting disclosure on burden grounds other than vaguely alleging that it will take too long and cost too much to comply. As far as the PSC is aware, none of the clinics provide information about the estimated time and expense that would be incurred in order to respond to the subpoena as issued. And many of the clinics have

<sup>&</sup>lt;sup>13</sup> By offering the following responses, many of which are based on the Accommodations, the PSC does not waive its right to otherwise challenge the correctness of the objections, or its right to later seek to obtain the documents originally requested.

<sup>&</sup>lt;sup>14</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>15</sup> Heidelberg Ams., Inc. v. Tokyo Kikai Seisakusho, Ltd., 333 F.3d 38 (1st Cir. 2003). The First Circuit upheld the district court's order quashing a subpoena served on a non-party that sought a decade's worth of materials, including any information relating to any business relationship with the plaintiff, and was not probative of the defendants' liability. Here, in contrast, the PSC's requests are limited to only four products and span only a little more than one year, and is undoubtedly related to NECC's and other parties' liability.

already gathered and produced much of the information requested in response to a Grand Jury Subpoena and requests from other governmental agencies.

In any event, this objection is addressed, if not mooted, by the PSC's Accommodations. The PSC took steps, both initially and in its Accommodations, to avoid imposing undue burden or expense on the subpoena recipients. Document requests relating to the identification of patients is narrowly tailored to only those patients who the clinics identify as having received administration of a contaminated NECC medication. The PSC has cut back the timeframe covered by almost all of its requests. The PSC will accept, in response to Request 6, lists of patients exposed to products the CDC has determined are contaminated that were previously create in response to governmental requests. The PSC is only seeking insurance policies that are applicable to the acts resulting in the administration of contaminated medications to patients. The PSC will waive the request to produce information about corporate structure, ownership, and organization. And the PSC will forgo most (if not all) record keeper depositions.

B. The requested documents are relevant and are reasonably calculated to lead to the discovery of admissible evidence

**Objection:** The requested documents are not relevant and/or not reasonably calculated to lead to the discovery of admissible evidence. <sup>17</sup>

**Response:** According to Federal Rule of Civil Procedure 26(a)(1), a party may seek information that is not directly related to issues raised by the pleadings if it is related in any way

<sup>&</sup>lt;sup>16</sup> Cont'l Datalabel, Inc. v. Avery Dennison Corp., 2010 U.S. Dist. LEXIS 68703 (D. Mass. June 15, 2010). The Honorable Richard Stearns noted that since the non-party recipient had already agreed complied with a 30(b)(6), professed no knowledge about other topics, and agreed to produce a witness for deposition, the serving party's insistence that the subpoena recipient produce documents reflecting "any consideration" of the subject of the patent infringement dispute was overreaching. Here, the subpoena recipients have, on the whole, not agreed to produce anything pursuant to the PSC's requests.

<sup>&</sup>lt;sup>17</sup> See Exhibit C for list of objections/motions to quash making this objection.

to the subject matter involved in the action upon a showing of good cause.<sup>18</sup> Good cause is shown when (1) the information sought is requested in a timely manner, (2) it does not appear that the information requested is cumulative or duplicative, and (3) the information requested may help to resolve the issues that are present in this case.<sup>19</sup>

Here, the PSC seeks, in part, information about purchases of contaminated products (Requests 1-4); what NECC told clinics, doctors, and/or health care providers about products it created and sold that were later found by the CDC to be contaminated; what clinics were told about NECC's qualifications and its compliance with USP standards (Requests 8 and 16); and communications between the clinics and NECC about recall notices (Requests 14 and 15). These requests all bear on NECC's liability and issues raised in the various complaints. The subpoenas are timely, are not seeking cumulative or duplicative information (see Section II. D), and will undoubtedly help to resolve matters at issue in the present case.

With the tailored scope of production contemplated in the Accommodations, the documents requested will serve the interests of establishing NECC's liability and identifying known and reasonably ascertainable personal injury and wrongful death claimants. Any narrowing of the document production beyond the Accommodations would severely inhibit the PSC's ability to develop its case and identify all known and reasonably ascertainable personal injury and wrongful death claimants.

#### C. The time periods given by the Accommodations are reasonable.

**Objection:** The time periods for which documents are requested are unreasonable.<sup>20</sup>

<sup>&</sup>lt;sup>18</sup> Sanchez-Medina v. Unicco Serv. Co., 265 F.R.D. 29 (D.P.R. 2010) (citing *In re Subpoena to Witzel*, 531 F.3d at 118); Fed.R.Civ.P. 26(a)(1).

<sup>&</sup>lt;sup>19</sup> *Id* 

<sup>14.</sup> 

<sup>&</sup>lt;sup>20</sup> See Exhibit C for list of objections/motions to quash making this objection.

**Response:** The Accommodations moot this objection. Some requests were originally open ended as to time. The revised requests ask for information from October 6, 2010 on (two years before the recall) as a default; some requests are even more limited, including those relating to the contaminated lots (all of which were produced in 2012).

# D. Most subpoenaed information cannot be obtained from public sources or from NECC.

**Objection:** The subpoena calls for the production of documents properly attainable by plaintiffs from public sources (CDC, FDA).<sup>21</sup>

**Response:** The PSC, along with the Creditors' Committee, has been in contact with the CDC about gaining access to materials. But, as discussed above, much of the information requested will not be in the government's possession.

Most clinics have not supported this objection with the identification of any requested documents that can be obtained from public sources. The PSC has requested the disclosure of any communications received by the clinics from the CDC, FDA or other governmental agencies concerning (a) NECC products and/or (b) the procurement of products from any compounding pharmacy. As to (a), the request is intended to reveal not only what public announcements were made about NECC products, but what announcements about NECC products the clinics actually received and information that the clinics sent in response. As to (b), this request has been eliminated in the Accommodations.

**Objection:** Many of the documents sought by the subpoena are more appropriately sought from NECC, thus reducing the burden and expense on the clinics.<sup>22</sup>

<sup>&</sup>lt;sup>21</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>22</sup> See Exhibit C for list of objections/motions to quash making this objection.

Response: Subpoena recipients' suggestions that a bankrupt entity facing hundreds of lawsuits brought by victims of this tragedy – who will never be able to pay victims the full value of their claims – should further deplete the limited resources it is endeavoring to retain for the benefit of victims by paying to produce information within clinics' possession reflects either a stunning lack of compassion or a failure to think through the consequences of shifting the expense.

Whether information may be discovered elsewhere is a factor for the Court to consider when weighing the subpoenas' benefits and burdens, but it is not determinative.<sup>23</sup> It is a highly case specific inquiry and entails an exercise of judicial discretion.<sup>24</sup> And "a person may not avoid a subpoena by saying that the evidence sought from him is obtainable from another."<sup>25</sup>

The bankruptcy stay currently prohibits the plaintiffs from serving any formal discovery requests on NECC. And while NECC may have some of this information, NECC does not have contact information for patients who received contaminated products, information about what the subpoena recipient considered when deciding whether to purchase products from NECC, information the clinic possessed about NECC's attempts to comply with USP requirements, or information the clinic possessed about the fitness of NECC's products for a particular purpose. Who better to provide information about what the clinic knew than the clinic?

#### II. JURISDICTIONAL AND PROCEDURAL OBJECTIONS

E. This Court has jurisdiction to centrally enforce the subpoenas.

**Objection:** This Court does not have jurisdiction to enforce the subpoena.<sup>26</sup>

<sup>25</sup> Covey Oil Co. v. Continental Oil Co., 340 F.2d 993 (10th Cir. 1965). See also

<sup>&</sup>lt;sup>23</sup> Wright and Miller, FEDERAL PRACTICE AND PROCEDURE, §2463.1 (2008 ed.).

 $<sup>^{24}</sup>$  Id

<sup>&</sup>lt;sup>26</sup> See Exhibit C for list of objections/motions to quash making this objection.

**Response:** This Court's jurisdiction to issue, enforce, and quash subpoenas cannot seriously be questioned.

MDL courts have authority to preside over coordinated or consolidated pretrial proceedings.<sup>27</sup> "Pretrial proceedings" have been liberally interpreted to give the MDL court control over all proceedings prior to trial.<sup>28</sup>

MDL courts have the authority to issue subpoenas pursuant to Fed. R. Civ. P. 30 & 45 and 28 U.S.C. § 1407(b). 28 U.S.C. 1407(b) explicitly references the MDL judge's enforcement power when it comes to conducting pretrial depositions: "[t]he judge or judges to whom [MDL] actions are assigned ... may exercise the powers of a district judge in any district for the purpose of conducting pretrial depositions in such coordinated or consolidated pretrial proceedings." Moore's Federal Practice notes that "[t]hough the statutory language refers to 'pretrial depositions,' the statute wisely has been interpreted to embrace document production subpoenas as well."

MDL courts can also quash subpoenas. According to Wright and Miller, "In multidistrict litigation, the court in charge of the consolidated proceedings has the power to rule on a motion to quash subpoenas." In the *Neurontin* MDL, Judge Sorokin concluded that the MDL court could compel production or quash a subpoena directed to an out of district nonparty:

<sup>&</sup>lt;sup>27</sup> 28 U.S.C. §1407.

<sup>&</sup>lt;sup>28</sup> See In re Neurontin Mktg., Sales Practices, and Prod. Liab. Litig., 245 F.D.R. 55, 57 (D. Mass. 2007). See also In re U.S. Office Prod. Co. Sec. Litig., 251 F.Supp.2d 58, 65 (D.D.C. 2003) ("In a multidistrict litigation action, the transferee judge has the same jurisdiction and power over pretrial proceedings that the transferor judge would have in the absence of the transfer.").

<sup>&</sup>lt;sup>29</sup> 28 U.S.C. §1407 (b).

<sup>&</sup>lt;sup>30</sup> See also 9-45 Moore's Federal Practice – Civil § 45.50(4). Some transferee courts have concluded that they do not have power to enforce subpoenas seeking documents only. See, e.g., Visx, Inc. v. Nidek Co., 208 F.R.D. 615 (N.D. Cal. 2002). This distinction has no bearing here. All of the subpoenas that the PSC presently intends to serve seek record keeper depositions as well as documents.

<sup>&</sup>lt;sup>31</sup> Wright and Miller, FEDERAL PRACTICE AND PROCEDURE, §2463.1 (2008 ed.). See also, In re Clients & Former Clients of Baron & Budd, P.C., 478 F.3d 670 (5th Cir. 2007); In re Subpoenas Served on Wilmer, Cutler &

...the MDL statute empowers an MDL judge to act as a judge of the deposition or discovery district. See 28 U.S.C. § 1407(b) ("The judge or judges to whom such [MDL] actions are assigned ... may exercise the powers of a district judge in any district for the purpose of conducting pretrial depositions in such coordinated or consolidated pretrial proceedings"). A judge presiding over an MDL case therefore may compel production by an extra-district nonparty; enforce, modify, or quash a subpoena directed to an extra-district nonparty; and hold an extra-district nonparty deponent in contempt, notwithstanding the nonparty's physical situs in a foreign district where discovery is being conducted.<sup>32</sup>

The Judicial Panel on Multidistrict Litigation agrees. In *In re Online DVD Rental*Antitrust Litigation, the Panel found that actions involving a motion to quash, brought by a third party subpoenaed by the MDL plaintiffs, were better decided by the transferee judge rather than a judge in another district with no particular knowledge of the MDL, where the third party was found to have important information central to the issues in the MDL. As the Panel put it, "requiring a judge in the Northern District of Texas to learn the particulars of MDL No. 2029 would not promote the just and efficient conduct of this action or the litigation as a whole[,]" and the "...litigation would be best served by allowing the transferee judge to determine the scope of discovery in the MDL."<sup>33</sup>

#### F. Plaintiffs may take discovery of nonparties.

**Objection:** The Clinic is not a party to any litigation and/or has no injured patients.<sup>34</sup>

**Response:** It is well settled that parties to lawsuits may take broad discovery of nonparties.<sup>35</sup> When a subpoenaed party seeks to resist discovery, even when that party is a nonparty, it is the subpoenaed party's burden to demonstrate that the discovery should not be

Pickering & Goodwin Proctor LLP, 255 F.Supp.2d 1(D.D.C. 2003); In re Subpoena Issued to Boies, Schiller & Flexner LLP, 2003 WL 1831426 (D.N.Y. 2003); HCA, Inc. v. U.S. ex. Rel. Pogue, 2002 WL 31953748 (D. Tn. 2002).

<sup>&</sup>lt;sup>32</sup> In re Neurontin Mktg., 245 F.R.D. 55, 58 (D. Mass. 2007), citing U.S. ex rel. Pogue v. Diabetes Treatment Centers of America, Inc., 444 F.3d 462, 468–469 (6th Cir. 2006).

<sup>&</sup>lt;sup>33</sup> In re Online DVD Rental Antitrust Litig., 744 F. Supp. 2d 1378 (J.P.M.L. 2010).

<sup>&</sup>lt;sup>34</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>35</sup> Fed.R.Civ.P. 45; Fed.R.Civ.P. 34(c).

permitted.<sup>36</sup> When analyzing whether a nonparty subpoena should be quashed, the court considers issues such as relevance, the requesting party's need, the breadth of the request, and the burden imposed.<sup>37</sup>

Among the most important objectives of the PSC in issuing these subpoenas is to identify all known and reasonably ascertainable personal injury and wrongful victims who received a contaminated product from NECC. By capitalizing on the work of the CDC and serving subpoenas only on those clinics identified by the CDC as having received the recalled lots of contaminated NECC medication, the burden imposed on such clinics is minimal, and the need is great. Many, if not all, of the clinics have already been required to identify such patients of theirs in response to grand jury subpoenas or requests for information from the CDC or their state health department.

Finally, an allegation that a clinic "has no injured patients" rings hollow in light of the recent journal articles disclosing an extremely long latency period and recurrence of symptoms.<sup>38</sup>

<sup>&</sup>lt;sup>36</sup> See e.g., Rockwell Automation, Inc. v. Kontron Modular Computers, Case No. 12-cv-566, 2013 U.S. Dist. LEXIS 2889, \* 3-4 (S.D. Cal. January 8, 2013) ("Under Fed. R. Civ. P. 45(a)(1)(C), a nonparty to a civil suit... can be subpoenaed for documents relevant to the suit...The burden is on the party resisting discovery to demonstrate that discovery should not be permitted."); Sham v. Hyannis Heritage House Hotel, Inc., 118 F.R.D. 24, 25 (D. Mass. 1987) ("The burden is upon the party resisting discovery to demonstrate that the matter being sought is indeed work-product as defined by Fed. R. Civ. P. 26(b)(3).")

<sup>&</sup>lt;sup>37</sup> Grider v. Keystone Health Plan Cent., Inc., 2005-MC-40, 2005 U.S. Dist. LEXIS 44069, 2005 WL 2030456, \*7 (M.D. Pa. July 28, 2005).

Malani A.N., Magnetic Resonance Imaging Screening to Identify Spinal and Paraspinal Infections Associated with Injections of Contaminated Methylprednisolone Acetate, JAMA 309(23):2465-2472 (June 19, 2013) ("a steady stream of spinal and paraspinal infections continue to present long after the injections were last administered."); Radiology: MRI May Spot Meningitis from Tainted Steroids, June 18, 2013 (36 of 172 individuals exposed to MPA screened had an abnormal MRI; of the 36, all but one met the CDC definition for probable (17 patients) or confirmed (18 patients) fungal spinal or paraspinal infection.); Morbidity and Mortality Weekly Report, 62(19);377-381. ("Patients with diagnosed spinal or paraspinal infections might not have signs and symptoms greater than their baseline levels."); Carol A. Kauffman et al., Fungal Infections Associated with contaminated Methylprednisplone Injections, N. Engl. J. Med. 368;26 (June 27, 2013) ("patients who had persistent back pain or peripheral-joint pain but who had a normal MRI study should ... be watched carefully and undergo repeated imaging if there was persistence or any increase in symptoms. Some patients had initially had normal imaging but subsequently were shown to have development of epidural abscess or phlegmom on follow-up MRI ...").

G. To the extent that the Court's orders limited the subpoenas' contents, the subpoenas comply with those Orders.

<u>**Objection:**</u> The subpoena imposes burdens other than or beyond those imposed by the Order on Central Enforcement and the Qualified Protective Order.<sup>39</sup>

Response: To the extent that the Court's previous orders limit the scope of what the PSC may seek, the PSC's subpoenas comply with those orders. The Order on Central Enforcement permits the PSC to obtain discovery over "Healthcare facilities and/or providers that have examined, tested or treated patients who have been identified as recipients of one or more of New England Compounding Pharmacy, Inc. ("NECC") solutions, medications or compounds, shall produce protected health information pursuant to this order and a subpoena issued by Plaintiffs."

The Order also permits the PSC to obtain discovery over "Pain clinics, hospitals, and other entities or individuals who purchased NECC's methylprednisolone acetate, cardioplegic solution, or ophthalmic solution."

And it provides for "any other information that lead counsel and the PSC reasonably determine necessary to the prosecution and resolution of these actions."

And, as discussed above, the Accommodations squarely address any concern, however meritless, raised that the subpoenas went beyond the scope of discovery permitted by these orders.

<sup>&</sup>lt;sup>39</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>40</sup> Oualified Protective Order, Dkt. No. 192 at ¶ 1.

<sup>&</sup>lt;sup>41</sup> Order on Central Enforcement, Dkt. No. 193.

<sup>&</sup>lt;sup>42</sup> See id. at  $\P$  2.

H. The subpoenas do not intentionally seek any privileged communications between attorneys and their clients.

**Objection:** The subpoena calls for the production of documents protected from disclosure as reflective of attorney-client communications and/or attorney work-product.<sup>43</sup>

Response: These objections are unfounded. The PSC has not requested any documents that would reasonably be expected to contain either attorney work-product or attorney-client communications. No subpoena recipient has specifically identified any document that falls into either of those categories. If a subpoena recipient has concerns related to specific, identified documents or categories of documents, the Plaintiffs' Steering Committee will meet and confer to resolve the issue (perhaps through the use of a privilege log).

I. If the PSC takes depositions pursuant to the subpoena, the attendance fee will be paid.

**Objection:** The PSC failed to provide the fee for one day's attendance as required by Rule 45(b)(1).<sup>44</sup>

**Response:** The PSC subpoenas included a deposition notice for a record keeper deposition. The PSC has since determined not to conduct records custodian depositions unless unique circumstances require the deposition to take place. The PSC will pay the required fee for all depositions that actually occur. For those depositions that may go forward and the witness fees were not contemporaneously served with the subpoena, the Court should permit the PSC to cure this technical defect by providing the witness fees prior to the deposition. 46

<sup>&</sup>lt;sup>43</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>44</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>45</sup> So far, the only depositions the PSC intends to conduct are in Tennessee.

<sup>&</sup>lt;sup>46</sup> See Adams v. Dolgencorp, LLC, Case No. 11-784, 2012 U.S. Dist. LEXIS 71066 (M.D. La. May 22, 2012) ("[W]hile a subpoena request without the witness fee is technically invalid, the defect can be cured.") (citing Meyer v. Foti, 720 F.Supp. 1234, 1244 (E.D.La. 1989).

#### J. Plaintiffs may seek discovery of parties through either Rule 45 or Rule 34.

**Objection:** Clinics that are parties should have been served a request for production pursuant to Fed. R. Civ. P. 34 rather than a subpoena pursuant to Fed. R. Civ. P 45.<sup>47</sup>

**Response:** It is well settled, that a party may use a Rule 45 subpoena to obtain discovery from a party. In *Badman v. Stark*, the Court held that, although Rule 34 applies only to parties, "a subpoena under Rule 45 may be served upon both party and non-party witnesses."

The text of Rule 45 compels this conclusion. As one federal court correctly held:

[T]here is no express limitation on the type of person who may be subject to the rule, as its language describes the individual upon whom a Rule 45 subpoena may be served simply as a "person" rather than a "non-party." Had the drafters of Rule 45 intended to restrict its scope to non-parties, they could easily have done so. Indeed, the separate and distinct use of the terms "person" and "person who is not a party" in the text of Rule 45 clearly demonstrates that the drafters were aware of the effect they would have on the scope of the rule's various provisions. <sup>50</sup>

Typically, parties are served with requests for production, rather than subpoenas. But this isn't always the case. And the distinction is one of form, not substance. If the PSC had elected

<sup>&</sup>lt;sup>47</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>48</sup> See e.g., United Steelworkers of Am. v. Gov't of the V.I., Case No. 2005-cv-0021, 2008 U.S. Dist. LEXIS 97916, \* 3-4 (D.V.I. 2005); Mortgage Information Services v. Kitchens, 210 F.R.D. 562, 563-66 (W.D.N.C. 2002); see also 9 Moore's Federal Practice § 45.03[1] (noting that "[s]ubpoenas under Rule 45 may be issued to parties or non-parties").

<sup>&</sup>lt;sup>49</sup> 139 F.R.D. 601, 603 (M.D. Pa. 1991) (citing *Continental Coatings Corp. v. Metco, Inc.*, 50 F.R.D. 382, 384 (N.D. Ill. 1970)). *See also First City, Texas-Houston, N.A. v. Rafidain Bank*, 197 F.R.D. 250, 255 n.5 (S.D.N.Y. 2000), aff'd, 281 F.3d 48 (2d Cir. 2002) ("While a Rule 45 subpoena is typically used to obtain the production of documents and/or testimony from a non-party to an action . . . nothing in the Federal Rules of Civil Procedure explicitly precludes the use of Rule 45 subpoenas against parties.") (citing *Badman*, 139 F.R.D. at 603).

<sup>&</sup>lt;sup>50</sup> Kitchens, 201 F.R.D. at 565 (cited by *United Steelworkers*, 2008 U.S. Dist. LEXIS 97916).

to serve requests for production rather than subpoenas, the recipient would be facing the exact same substantive requests for production and, by default, a much more aggressive timeline.<sup>51</sup>

#### K. The subpoenas were served in compliance with the Federal Rules.

**Objection:** The subpoena was improperly served via Federal Express.<sup>52</sup>

**Response:** Numerous courts have found that a subpoena may be served via Federal Express.<sup>53</sup>

The text of Rule 45 compels this conclusion. Rule 45(b)(1), provides in pertinent part as follows: "Service of a subpoena upon a person named therein shall be made by delivering a copy thereof to such person. . . ." Courts have determined that nothing in the plain language of the Rule requires personal service. <sup>54</sup> And Courts have held that service by certified mail or Federal Express is sufficient. <sup>55</sup>

<sup>&</sup>lt;sup>51</sup> Fed.R.Civ.P. 34(b)(2)(A) ("the party to whom the request is directed must respond in writing within 30 days after being served.").

<sup>&</sup>lt;sup>52</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>53</sup> See e.g., SEC v. Rex Venture Group, LLC, Case No. 5:13-MC-004, 2013 U.S. Dist. LEXIS 44564 (M.D. Fla. March 28, 2013); In re Subpoena Duces Tecum, Case No. 3:12-mc-0078, 2012 U.S. Dist. LEXIS 175871 (M.D. Tenn. December 10, 2012); TracFone Wireless, Inc. v. Technopark Co., Ltd., 281 F.R.D. 683 (S.D. Fla.); Hall v. Sullivan, 229 F.R.D. 501 (D. Md. 2005); Western Res., Inc. v. Union Pac. R.R., 2002 U.S. Dist. LEXIS 14897, 2002 WL 1822432 (D. Kan.2002).

<sup>&</sup>lt;sup>54</sup> See King v. Crown Plastering Corp., 170 F.R.D. 355, 356 (E.D.N.Y. 1997) (no need for personal service of Rule 45 subpoena "so long as service is made in a manner that reasonably insures actual receipt of the subpoena by the witness"); *Doe v. Hersemann*, 155 F.R.D. 630, 630-631 (N.D. Ind. 1994) ("The plain language of the rule requires only that the subpoena be delivered to the person served by a qualified person"); *Ultradent Prods., Inc. v. Hayman*, 2002 U.S. Dist. LEXIS 18000, 2002 WL 31119425 (S.D.N.Y.2002) (finding that although delivery to the person was required, delivery did not require personal in-hand service);

<sup>&</sup>lt;sup>55</sup> See, e.g., Doe v. Hersemann, 155 F.R.D. 630 (N.D. Ind.1994) (holding that service of a subpoena via certified mail is sufficient under Rule 45, particularly when Defendant does not deny actual receipt); Western Res., Inc. v. Union Pac. R.R., 2002 U.S. Dist. LEXIS 14897 (D. Kan.2002) (holding that delivery of subpoena via Federal Express was sufficient because effective service under Rule 45 is not limited to personal service).

#### L. By definition, the subpoenas are limited to information in the recipient's possess, custody, or control.

The subpoena calls for the production of documents outside the clinic's **Objection:** possession, custody or control.<sup>56</sup>

Rule 45 explicitly limits its scope to the production of documents within Response: the subpoenaed party's "possession, custody, or control."<sup>57</sup> Obviously, the PSC cannot expand the scope of the rule and it need not explicitly state that the documents required be produced be in the possession, custody, or control of the party.<sup>58</sup> Therefore, all documents identified in the subpoena for production are, by definition, limited to the documents that any clinic would ordinarily keep within its possession, custody, or control.

#### M. The time to respond proposed in the Accommodations is reasonable.

The subpoena provided only 21 or 30 days to respond, which is not a **Objection:** reasonable amount of time.

No subpoenaed issued required the production of documents in less time **Response:** than three weeks. There is a wealth of case law holding that 21 days to comply with a subpoena is reasonable under Rule 45.<sup>59</sup>

person to produce documents within his or her possession, custody, or control).

<sup>&</sup>lt;sup>56</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>57</sup> Fed. R. Civ. P. 45(a)(1)(A)(iii).

<sup>&</sup>lt;sup>58</sup> See, e.g., United States EPA v. GE, 197 F.3d 592 (2d Cir. 1999) (noting that Rule 45 is limited to requiring a

<sup>&</sup>lt;sup>59</sup> See, e.g., Lowe v. Vadlamudi, Case No. 08-10269, 2012 U.S. Dist. LEXIS 127586 (E.D. Mich. Sept. 7, 2012) ("The text of Rule 45 does not support this argument, and the Court finds that twenty-one days is a reasonable time to comply."); Linke Enterprises of Oregon, Inc. v. Champion Lab. Inc., Case No. 90-544, 1991 U.S. Dist. LEXIS 7155 (D. Ore. May 20, 1991) (holding that party is entitled to a reasonable time to comply under Rule 45 and permitting 21 days for compliance); see also Thomas v. Rockin D Marine Servs., LLC, Case No. 12-1315, 2013 U.S. Dist. LEXIS 60007 (E.D. La. April 25, 2013) (fourteen days is reasonable time to comply with subpoena); Mann v. Univ. of Cincinnati, 114 F.3d 1188 (Table), Nos. 95-3195, 95-3292, [published in full-text format at 1997 U.S. App. LEXIS 12482], (6th Cir. May 27, 1997) (approving magistrate judge's finding that fourteen days' notice is reasonable).

Most of the subpoenas were served weeks ago. And the PSC's Accommodations, including the narrowing of the requests to produce and the offer to extend the deadline for producing documents until August 15 for recipients who agree to produce materials on a rolling basis, most this objection.

N. Parties to the MDL knew subpoenas were going out to clinics and received copies of the subpoenas actually issued.

Objection: Federal Rule of Civil Procedure 45(b)(1) requires that subpoenas be served on each party to the MDL. Comments to the Rule say that parties should have been given notice before service of the subpoenas on third parties.

**Response:** A subpoena recipient – particularly a non-party – cannot avoid the reach of a subpoena by arguing that the PSC failed to give notice to another party.<sup>60</sup> But, in any case, the PSC adequately provided notice to defendants both before and after the subpoenas issued, which is sufficient under Rule 45 to satisfy the notice requirements.

The Plaintiffs' Steering Committee informed the Court and the defendants that it intended to issue subpoenas to clinics, doctors, and/or other health care providers months before the subpoenas went out. The Court entered multiple orders permitting and addressing these subpoenas. The PSC shared copies of the attachment to the subpoena requesting documents with counsel then of record in the MDL – and incorporated comments from the defendants – before the subpoena went out. Copies of each subpoena were sent to counsel for all defendants then of record following service of the subpoenas, both by the counsel issuing the subpoena (*see* service

LLC, 275 F.R.D. 251 (S.D. Ohio 2011) (same).

<sup>&</sup>lt;sup>60</sup> See, e.g., Bare v. Brand Energy & Infrastructure Servs., Case No. 09-807 2012 U.S. Dist. LEXIS 153881 (D. Utah October 24, 2012) (refusing to quash subpoena on grounds of failure to provide each party with pre-service notice because "the opposing party has had a sufficient opportunity, albeit after the subpoena had been served, to object to the subpoena."); Steel Works Rebar Fabricators, LLC v. Alterra Am. Ins. Co., Case No. 11-24032, 2012 U.S. Dist. LEXIS 72985 (S.D. Fla. May 25, 2012) (refusing to quash subpoena for lack of notice to each party when party cannot demonstrate any prejudice suffered for lack of timely notice); Hendricks v. Total Quality Logistics,

lists accompanying each subpoena) and – as an added precaution – by the Plaintiffs' Steering Committee.

#### III. CONFIDENTIALITY OBJECTIONS

O. The Protective Order will protect confidential information.

**Objection:** The subpoena calls for the production of confidential or proprietary business information.<sup>61</sup>

Response: On July 12, 2013 the Court entered the Stipulated Protective Order of Confidentiality, pursuant to which "persons producing discovery material, including non-parties to this litigation, . . . may designate as "Confidential Discovery Material" information the producing party believes is entitled to protection pursuant to this Order." The Court identifies "[t]rade secrets, or other confidential or proprietary research, development, manufacturing or commercial or business information" as being specifically among those categories of information eligible for protection under the Order. The disclosing parties need only designate such information as Confidential Discovery Material to ensure that such information is afforded all the protections under the Order. The order of the protections under the Order.

P. The Court's Orders, the selected vendor, and the process provided for producing protected health information comply with HIPAA.

Objection: The subpoena calls for the production of documents protected from disclosure under the doctor-patient privilege, and/or the production of which would violate the

<sup>&</sup>lt;sup>61</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>62</sup> Dkt. No. 280, ¶ 2.

<sup>&</sup>lt;sup>63</sup> *Id*.

<sup>&</sup>lt;sup>64</sup> The Plaintiffs' Steering Committee reserves the right to challenge the confidentiality of any materials designated "confidential"

requirements of the Health Insurance Portability and Accountability Act and its related regulations.65

It has become de rigueur for state of the art notice plans in class actions **Response:** and bankruptcies to include subpoening the name and contact information of potential class members or bankruptcy claimants from non-parties for purposes of providing notice to those individuals. Any ethical, responsible attorney would endeavor to collect this information in order to provide actual notice to victims. On the class action side, the notice discloses certification of a class and/or provides an opportunity to opt in to, or out of, a settlement.<sup>66</sup> Sometimes, collecting the name of individuals who took a particular drug allows checks to be sent directly to consumers (without requiring them to do more than take a trip to the bank). On the bankruptcy side, the notice discloses a date by which claims against the estate must be filed.

Plaintiffs' have already provided the Court with 13 examples<sup>67</sup> where patients' names and contact information were produced (only) to a qualified vendor who held the information in a manner compliant with HIPAA and, pursuant to a later Court order, used the information for purposes of sending notice. And Rust/Omni, the vendor the PSC has retained to receive

<sup>&</sup>lt;sup>65</sup> See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>66</sup> We refer to class actions by way of an example where courts routinely approve collecting protected health information for purposes of notice; not because the PSC intends to pursue class certification or a class settlement.

<sup>&</sup>lt;sup>67</sup> Commonwealth Care Alliance v. Astrazeneca Pharmaceuticals L.P., 05-0269-BLS, Dkt. No. 169 (Suffolk Sup. Dec. 20, 2012) (Sanders, J.); In re Relafen Antitrust Litig. v. Smithkline Beecham Corp., 2004 U.S. Dist. LEXIS 29834, at \*17-18 (D. Mass, Nov. 24, 2004) (Young, J.); In re Pharmaceutical Industry Average Wholesale Price Litig., 01-CV-12257-PBS, Dkt. No. 5455 (D. Mass. July 21, 2008) (Saris, J.); In re Pharmaceutical Industry Average Wholesale Price Litig., 01-CV-12257-PBS, Dkt. No. 865 (D. Mass. June 8, 2004) (Saris, J.); Government Employees Hosp. Ass'n v. Serono Int', I.S.A., 05-cv-11935-PBS, Dkt. No. 109 (D. Mass. July 13, 2007) (Saris, J.); New England Carpenters Health Benefits Fund v. First Databank, Inc., 05-cv-11148-PBS, Dkt. No. 139 (D. Mass. 2006) (Saris, J.); In re Visa Check/Mastermoney Antitrust Litig., 2002 U.S. Dist. LEXIS 23327, at \*6-7 (E.D.N.Y. June 21, 2002); Mercier v. Courtyard Nursing Care Ctr., 25 Mass. L. Rep. 461 (Mass. Super. Ct. 2009); In re Bextra and Celebrex Marketing, Sales Practices and Prod. Liab. Litig., 05-CV-01699-CRB, Dkt. No. 2595 (N.D. Cal. Dec. 8, 2008) (Brever, J.); Commonwealth of Virginia v. McKesson Corporation, 11-02782-SI, Dkt. No. 31 (N.D. Cal. Dec. 12, 2011) (Illston, J.); In re Tricor Indirect Purchaser Antitrust Litig., 05-cv-00360-SLR, Dkt. No. 510 (D. Del. May 8, 2009) (Robinson, J.); In re Tricor Indirect Purchaser Antitrust Litig., 05-cv-00360-SLR, Dkt. No. 558 (D. Del. Feb. 2, 2010) (Robinson, J.); In re Actiq Sales and Mktg. Practices Litig., 07-cv-04492-PBT, Dkt. No. 293 (E.D. Penn. Sept. 7, 2011) (Tucker, J.).

protected health information here, listed thirteen examples where it had obtained protected health information in the context of a bankruptcy. <sup>68</sup>

The Court and the PSC have gone to great lengths to ensure that procedures are in place to ensure compliance with HIPAA and the protection of individuals' Personal Health Information, including the following:

- (i). The Court entered the Qualified Protective Order, which provides the limited circumstances under which Personal Health Information will be disclosed. Among other things the Order requires the identification of a Vendor which shall hold the protected health information "in the strictest confidence and shall not release such information to any other person or entity until further order of this Court." In the Order, the Court also provided that "[a]ll subpoenaed entities that provide requested information shall be deemed to fall within the safe harbor of HIPAA for court-ordered production of personal health information, . . . and shall have no liability under HIPAA or any other federal or state statute, regulation, or other requirement related to protected health information, for supplying patient or member information to the Vendor."
- (ii). In its Corrected Notice of Identification of Document Repository Vendors, the PSC identified Rust Consulting Omni Bankruptcy as the designated repository for all documents containing Personal Health Information.<sup>71</sup>

<sup>&</sup>lt;sup>68</sup> In Re Owens Corning, LLC, Case No. 00-03837 (JKF), United States Bankruptcy Court District Of Delaware; In Re W.R. Grace, Case No. 01-01139 (JFK), United States Bankruptcy Court District Of Delaware; In Re Artra Group, Ltd., Case No. 02-A 01086, United States Bankruptcy Court Northern District Of Illinois, Eastern Division; In Re Christian Brothers Institute, Case No.: 11-22820 (RDD), United States Bankruptcy Court For The Southern District Of New York; In Re Society of Jesus, Oregon Province, Case No. 09-3093, United States Bankruptcy Court District Of Oregon; In Re Downey Regional Medical Center, Case No. 2:09-bk-34714-SB, United States Bankruptcy Court Central District Of California.

<sup>&</sup>lt;sup>69</sup> Qualified Protective Order, ¶ 4.

 $<sup>^{70}</sup>$  Id. at ¶ 11.

<sup>&</sup>lt;sup>71</sup> Dkt. No. 237.

(iii). In his affidavit filed in support of the Qualified Protective Order, Brian Osborne, President of Rust Consulting Omni Bankruptcy swore, inter alia, that he had reviewed the Qualified Protective Order, that his company is qualified to meet the obligations outlined in the Order, and that his company "shall hold such protected health information in the strictest confidence and shall not release such information to any other person or entity until further order of the Court."

#### IV. MOTIVE OBJECTIONS

Q. The PSC is doing its job, not trolling for clients.

**Objection:** The PSC's subpoenas are thinly veiled attempts to identify new clients.<sup>73</sup>

Response: Protected health information, including patient names and contact information, will be produced to a HIPAA-compliant vendor and held by that vendor until a Court issues an order permitting that data to be used for notice purposes. The PSC will not have access to patient names and thus could not possibly use that information to try to drum up clients.

The Chapter 11 Trustee has filed a Motion to Bar Date in the Bankruptcy Court, asking that Court to require all creditors – including tort victims – to file a proof of claim against NECC by September 20, 2013. The PSC proposes having a qualified vendor use this patient identifying information for the purposes of notifying potential claimants about any bar date.

Why does the PSC care about who gets notice of the bar date? Because a bar date, and the later confirmation of a bankruptcy plan, will extinguish tort victims' claims against NECC. Including victims who are, or will be, represented by the PSC in the MDL.<sup>74</sup>

DRt. 110. 224

<sup>&</sup>lt;sup>72</sup> Dkt. No. 224.

 $<sup>^{73}</sup>$  See Exhibit C for list of objections/motions to quash making this objection.

<sup>&</sup>lt;sup>74</sup> The members of the Plaintiffs' Steering Committee, and other lawyers across the country, represent many victims who have yet to file a lawsuit.

The CDC has stated that at least 13,000 people were potentially exposed to NECC's contaminated products. It is imperative that all potential claimants be identified and sent actual notice well before the bar date. Otherwise the due process rights of potentially hundreds of individuals will be violated for lack of notice that their claim against NECC was extinguished in the bankruptcy proceeding. The Court should ensure that, at minimum, the victims' identifying information be produced, according to the safe guards already in place.

#### **CONCLUSION**

None of the arguments raised in the objections and motions to quash subpoenas issued to clinics, doctors, and/or health care providers undercut the served subpoenas. The Court should deny the motions to quash and reject the objections, particularly in light of the PSC's Accommodations.

Dated: July 17, 2013 Respectfully Submitted,

#### /s/ Kristen Johnson Parker

Thomas M. Sobol Kristen Johnson Parker HAGENS BERMAN SOBOL SHAPIRO LLP 55 Cambridge Parkway, Suite 301 Cambridge, MA 02142 Phone: (617) 482-3700

Fax: (617) 482-3700 Fax: (617) 482-3003 tom@hbsslaw.com kristenjp@hbsslaw.com

Plaintiffs' Lead Counsel

Elizabeth J. Cabraser
Mark P. Chalos
LIEFF CABRASER HEIMANN &
BERNSTEIN, LLP
275 Battery Street, 29th Floor
San Francisco, CA 94111
Phone: (415) 956-1000

Fax: (415) 956-1008 ecabraser@lchb.com

#### mchalos@lchb.com

#### Federal/State Liaison

Marc E. Lipton LIPTON LAW 18930 W. 10 Mile Road Southfield, MI 48075 Phone: (248) 557-1688 Fax: (248) 557-6344 marc@liptonlawcenter.com

Kimberly A. Dougherty JANET, JENNER & SUGGS, LLC 31 St. James Avenue Suite 365 Boston, MA 02116 Phone: (617) 933-1265 kdougherty@myadvocates.com

Patrick T. Fennell CRANDALL & KATT 366 Elm Avenue, S.W. Roanoke, Virginia 24016 Phone: (540) 342-2000 pfennell@crandalllaw.com

J. Gerard Stranch, IV
Benjamin A. Gastel
BRANSETTER, STRANCH & JENNINGS
PLLC
227 Second Avenue North
Nashville, TN 37201
Phone: (615) 254-8801
Fax: (615) 255-5419
gerards@branstetterlaw.com

Mark Zamora
ZAMORA FIRM
6 Concourse Parkway, 22nd Floor
Atlanta, GA 30328
Phone: (404) 451-7781
Fax: (404) 506-9223
mark@markzamora.com

Plaintiffs' Steering Committee

**CERTIFICATE OF SERVICE** 

I, Kristen Johnson Parker, hereby certify that I caused a copy of the foregoing Motion for

Entry of Stipulated Protective Order of Confidentiality and proposed stipulated protective order

of confidentiality to be filed electronically via the Court's electronic filing system. Those

attorneys who are registered with the Court's electronic filing system may access these filings

through the Court's system, and notice of these filings will be sent to these parties by operation

of the Court's electronic filing system.

Dated: July 17, 2013

/s/ Kristen Johnson Parker

Kristen Johnson Parker, BBO # 667261

### **EXHIBIT A**

### List of Subpoenaed Clinics, Doctors, and/or Health Care Providers

#### **Facility Street**

		Facility Street		
	Facility Name	<u>Address</u>	Facility City	Facility State
1				
	Cypress Surgery Center a/k/a			
	Sequoia Surgical Center	842 S. Akers Street	Visalia	California
2		16311 Ventura		
	Encino Outpatient Surgicenter	Boulevard	Encino	California
3	Litelio Outpatient Surgicenter	Boulevaru	LIICIIIO	Camornia
3		275.11 11 15 1		0.115
	Ukiah Valley Medical Center	275 Hospital Drive	Ukiah	California
4		819 Auto Center		
	Universal Pain Management	Drive	Palmdale	California
5	Interventional Spine and Sports	1625 Straits		
	Med	Turnpike, Suite 205	Middlebury	Connecticut
6	Interventional Rehabilitation	1549 Airport Blvd,		
	Center	Suite 420	Pensacola	Florida
7			Palm Beach	
	North County Surgicenter	4000 Burns Road	Gardens	Florida
8			Gardens	Tioriua
	Orlando Center for Outpatient	1405 S. Orange		et. da
	Surgery	Ave, # 400	Orlando	Florida
9	Pain Consultants of West	4624 North Davis		
	Florida	Highway	Pensacola	Florida
10	Surgical Park Center	9100 SW 87th Ave.	Miami	Florida
11				
	Forsyth Street Ambulatory	1600-1610 Forsyth		
	Surgery Center	Street	Macon	Georgia
12	,	2375 E. Sunnyside		J
	Pain Specialists of Idaho	Road, Suite F	Idaho Falls	Idaho
13	Tam Specialists of Idams		Taario Tario	TGG110
	Walter Knox Memorial Hospital	1202 E. Locust Street	Emmett	Idaho
14	·		Lillinett	luano
14	APAC Centers for Pain	2860 North		
4.5	Management	Broadway Street	Chicago	Illinois
15	APAC Centers for Pain	2450 S. Wolf Road,		
	Management	Suite D	Westchester	Illinois
16		850 W. Irving Park		
	Thorek Memorial Hospital	Road	Chicago	Illinois
17		1125 Professional		
	Ambulatory Care Center LLC	Blvd.	Evansville	Indiana
18		5740 Coventry		
	Fort Wayne Physical Medicine	Lane, Suite 101	Fort Wayne	Indiana
			. Sie itayiie	maiana

19	OSMC Outpatient Surgery	2310 California		
	Center	Road	Elkhart	Indiana
20		211 North Eddy		
24	South Bend Clinic	Street	South Bend	Indiana
21	Union Hospital	1606 N. 7th Street	Terre Haute	Indiana
22	Wellspring Pain Solutions	2400 North Park, Suite 20	Columbus	Indiana
23	Baltimore Pain Management	9110 Philadelphia Road, Suite 306	Baltimore	Maryland
24	Berlin Interventional Pain	10308 Old Ocean		1
	Management	City Blvd.	Berlin	Maryland
25	Management	100 Walter Ward	Bernin	iviaryiana
23	Box Hill Surgery Center	Blvd, Suite 300	Abingdon	Maryland
26	Box Hill Surgery Center	·	Abiliguoli	iviai yiaiiu
20	Caranania a Camana Camban	2700 Quarry Lake	Daltiman	N 4 a m da m d
27	Greenspring Surgery Center	Drive	Baltimore	Maryland
27	Harford County ASC, LLC	1952 A. Pulaski	Edgewood	Mandand
28	Hariord County ASC, LLC	Highway	Eugewood	Maryland
20		8322 Bellona Ave.,	_	
20	Pain Medicine Specialists	Suite 330	Towson	Maryland
29	Surgcenter of Bel Air	209 Thomas Street	Bel Air	Maryland
30	Greater Baltimore Medical	6701 North Charles		
	Center	Street		Maryland
31		659 South		
	Salisbury Immediate Care	Salisbury Blvd.,		
	Center	Suite 2		Maryland
32	Michigan Neurosurgical	4620 Genesys		
	Institute	Parkway	Grand Blanc	Michigan
33		2305 Genoa		
		Business Park		
	Michigan Pain Specialists	Drive, Suite 210	Brighton	Michigan
34	Neuromuscular &	3988 West Royal		
	Rehabilitation	Drive	Traverse City	Michigan
35	Southeast Michigan Surgical	21230 Dequindre		
	Hospital	Road	Warren	Michigan
36		2104 Northdale		
	MAPS-Edina Medical Pain Clinic	Blvd., Suite 220	Fridley	Minnesota
37		2104 Northdale		
	MAPS- Medical Advanced Pain	Blvd., Suite 220	Fridley	Minnesota
38	Medical Advanced Pain	1601 St. Fancis	·	
	Specialists	Avenue, Suite 200	Shakopee	Minnesota
39	Medical Advanced Pain	22., 20 200		
	Specialists		Maple Grove	Minnesota
	- Specialists	l	I WIGHT GIOVE	wiiiiiC3Ota

40		7400 France		
	Minnesota Surgery Center	Aveneu S.	Minneapolis	Minnesota
41		9550 Upland Lane	·	
	Minnesota Surgery Center	North, Suite 150	Maple Grove	Minnesota
42	High Point Surgery	600 Lindsay Street	Hight Point	North Carolina
43	North Carolina Orthopaedic	3609 Southwest		
	Clinic	Durham Drive	Durhmam	North Carolina
44				
	Surgery Center of Wilson d/b/a			
	Eastern Regional Surgery	1709 Medical Park	NA CI	
45	Center	Drive West	Wilson	North Carolina
45	Dr. O'Connell's Pain Care	2299 Woodbury	Newigates	Nov. Homenshine
46	Center	Avenue	Newington	New Hampshire
40	Dr. O'Connell's Pain Care Center, Inc	1 Mound Court	Merrimack	New Hampshire
47	Center, inc	1 Mount Court	Merrinack	пем патіряті
',	Central Jersey Orthopedics	1907 Park Avenue,		
	Specialists PC	Suite 102	South Plainfield	New Jersey
48		10 Parsonage		
	Edison Surgical Center	Road, #206	Edison	New Jersey
49	If Pain Associates/ Isaiah	222 Cedar Lane,		·
	Florence	Suite 210	Teaneck	New Jersey
50	Premier Orthopedics Surg.	298 South Delsea		
	Assoc., LLC	Drive	Vineland	New Jersey
51	Comprehensive Pain			
	Management	540 Lafayette Road	Sparta	New Jersey
52		1505 West		
	South Jersey Health Care	Sherman	Vineland	New Jersey
53		501 West Front		
54	South Jersey Health Care	Street 2401 Paseo Del	Elmer	New Jersey
54	Sahara Surgery Center	Prado	Las Vegas	Nevada
55	Sanara Sargery Center	184 Old Country	203 7 6 8 0 3	Nevada
	Butani, Sunil H., Physician PC	Road	Mineola	New York
56	, , , , , , , , , , , , , , , , , , , ,	140 Stevens		
	Obosa Medical Services	Avenue	Mount Vernon	New York
57		400 Red Creek		
	Rochester Brain and Spine	Drive, Suite 120	Rochester	New York
58		1065 Delaware		
	BKC Pain Specialists, LLC	Avenue, Suite A	Marion	Ohio
59		8261 Cornell Road,		
	Cincinnati Pain Management	Suite 630	Cincinnati	Ohio

60	1	1199 Delaware	I	
	Marion Pain Clinic	Avenue	Marion	Ohio
61				
	Ortho-Spine Rehabilitation	7211 Sawmill Road,		
	Center, Inc	Suite 101	Dublin	Ohio
62	,			
	Allegheny Pain Management	1402 Ninth Street	Altoona	Pennsylvania
63	South Hills Pain & Rehab	575 Coal Valley		
	Associates	Road, Suite 277	Jefferson Hills	Pennsylvania
64		595 West State		
	Doylestown Hospital	Street		Pennsylvania
65	Holy Redeemer Ambulatory	821 Huntingdon		
	Surgery	Pike		Pennsylvania
66		935 Jefferson Blvd.,		
	New England Anesthesiology	Suite 1002	Warwick	Rhode Island
67		6 Blackstone Valley		
		Place, Suite 21,		
	Ocean State Pain Management	Building 2	Lincoln	Rhode Island
68		1377 South County		
	Ocean State Pain Management	Trail	East Greenwich	Rhode Island
69		1341 Old		
	Intervene MD	Georgetown Road, Suite B	Mount Pleasant	South Carolina
70	Intervene MD		Mount Pleasant	30utii Carollila
/0	PCA Pain Care Center	200 New York Avenue, Suite 320	Oak Ridge	Tennessee
71	rea rain care center	Avenue, Juite 320	Oak Muge	Termessee
' -	Specialty Surgery Center	116 Brown Avenue	Crossville	Tennessee
72			Crossville	Termessee
-	St. Thomas Outpatient Neurosurgical	4320 Harding Pike, F19	Nashville	Tennessee
73	i veui osui gicai	200 New York	IAGSHAILE	Termessee
	Donald Jones, M.D.	Avenue, Suite 320	Oak Ridge	Tennessee
74	Domaid Jones, Wi.D.	Avenue, June 320	Jun Mage	Termessee
	Erlanger Health Systems	975 E. Third Street	Chattanooga	Tennessee
75	Chattanooga Neurosurgery &	1010 E. Third	Shattanooga	. cimessee
	Spine	Street, Suite 202	Chattanooga	Tennessee
76	55	102 Woodmont	Shactanooga	Termessee
	St. Thomas Health	Blvd., Suite 800	Nashville	Tennessee
77	2	2011 Murphy	. tuonii me	
	Howell Allen Clinic, P.C.	Avenue, Suite 301	Nashville	Tennessee
78		102 Woodmont	. tuonii me	
	St. Thomas Hospital	Blvd. Suite 800	Nashville	Tennessee
79	St. Thomas Network	4220 Harding Pike	Nashville	Tennessee

## 

80	Martin Kelvas (Former St.	102 Woodmont		
	Thomas Hospital Employee)	Blvd., Suite 800	Nashville	Tennessee
81	HCA Health Services of			
	Tennessee (Centennial Medical			
	Center)	1 Park Plz	Nashville	Tennessee
82				
	Insight Imaging-Roanoke	2923 Franklin Road		Virginia
83	New River Valley Surgery			
	Center	2901 Lamb Circle	Christiansburg	Virginia
84	Insight Health Corp.	2923 Franklin Road		Virginia
85		1212 Garfield		
	PARS Interventional Pain	Avenue, Suite 202	Parkersburg	West Virginia

# Coase-11123-mid-082419-F2MS Document 325-2 Filed 07/17/13 Page 420+156 EXHIBIT B

Objector	Neurosurgical Group of Chattanooga	St. Thomas Outpatient Neurological Center	Surgery	Howell Allen Clinic, PLLC	Dr. Donald Jones	Liberty Industries, Inc. & Mot. in Support thereof	Southeast Michigan Surgial Hospital	Michigan Pain Specialists	Thorek Memorial Hospital	Erlanger Health Systems, Inc.	Surgery Center Associates of High Point, LLC	Premier Orthopedic	Baltimore Pain Management Center
Docket Entry #	218	219	220	221	222	231 & 232	236	241	244	246, 247, 248, 256	250	252	254
State	TN	TN	TN	TN	TN	СТ	МІ	МІ	IL	TN	NC	NJ	MD
I. BURDEN (i.e., time, expense, and scope) OBJECTIONS													
A. The request for production of documents is overly broad and unduly burdensome.	х	х	х	х	х	х	х	х	х	х	х		
B. The requested documents are not relevant and/or not reasonably calculated to lead to the discovery of admissable evidence.	х	х	х	х	х	х	х	х	х	х	Х		х
C. The time periods for which documents are requested are unreasonable.													
D. The subpoena calls for the production of documents properly attainable by plaintiffs from public sources (CDC, FDA).											х		
Many of the documents sought by the subpoena are more appropiatly sought from NECC, thus reducing the burden and expense on the clinics.													

# Coase-11123-mid-082419-F2MS Document 325-2 Filed 07/17/13 Page 23-09/156 EXHIBIT B

Objector	Carilion Surgery Center New River Valley	North Carolina Orthopedic Clinic	HCA Health Services of Tennessee (Centennial Medical Center)	Surgical Park Center, Ltd.	Kelvas	St. Thomas Outpatient Neurological Center			Surgery Center of Wilson, LLC		Neuromuscular and Rehabilitation Associates of Northern Michigan
Docket Entry #	257	259	260	261	263	266	269 & 270	273	275	279	288
State	VA	NC	TN	FL	GA	TN	IN	NJ	NC	GA	MI
I. BURDEN (i.e., time, expense, and scope) OBJECTIONS											
A. The request for production of documents is overly broad and unduly burdensome.			х	х				Х			
B. The requested documents are not relevant and/or not reasonably calculated to lead to the discovery of admissable evidence.	х	х	х	х	Х	х	х	х	х		х
C. The time periods for which documents are requested are unreasonable.			х	х							
D. The subpoena calls for the production of documents properly attainable by plaintiffs from public sources (CDC, FDA).			Х	х							
Many of the documents sought by the subpoena are more appropiatly sought from NECC, thus reducing the burden and expense on the clinics.							х				

# Coase-11123-mid-082419-F2MS Document 325-2 Filed 07/17/13 Page 34-09/156 EXHIBIT B

	Rochester Brain	Insight Health	Inspira Health	Pain	Dr. O'Connell's	Greenspring	Pain
	and Spine	Corp.	Network, Inc. and	Associates of	Pain Care	Surgery Center	Consultants of
Objector	Neurosurgery &		Inspira Medical	Charleston	Center		West Florida
	Pain		Center, Inc.				
Docket Entry							
#							
State							
I. BURDEN (i.e., time, expense, and scope) OBJECTIONS							
A. The request for production of documents is							
overly broad and unduly burdensome.	Х	Х	Х	Х	Х		Х
B. The requested documents are not relevant							
and/or not reasonably calculated to lead to the	X		X	X	×		Х
discovery of admissable evidence.							^
C. The time periods for which documents are							
requested are unreasonable.							
D. The subpoena calls for the production of							
documents properly attainable by plaintiffs from	Х						Х
public sources (CDC, FDA).							
Many of the documents sought by the subpoena							
are more appropiatly sought from NECC, thus	x						х
reducing the burden and expense on the clinics.	_ ^						<b>^</b>

# Coase-11123-mid-082419-F2MS Document 325-2 Filed 07/19/13 Page 45-09/156 EXHIBIT B

Objector	Neurosurgical Group of Chattanooga	St. Thomas Outpatient Neurological Center	Specialty Surgery Center, PLLC	Howell Allen Clinic, PLLC	Dr. Donald Jones	Liberty Industries, Inc. & Mot. in Support thereof	Southeast Michigan Surgial Hospital	Michigan Pain Specialists	Thorek Memorial Hospital	Erlanger Health Systems, Inc.	Surgery Center Associates of High Point, LLC		Baltimore Pain Management Center
II. JURISDICTIONAL AND PROCEDURAL OBJECTIONS													
E. This court does not have jurisdiction to enforce the subpoena.	е								х				
F. The clinic is not a party to any litigation and/or has no injured patients.							х	х		х	х		х
G. The subpoena imposes burdens other than or beyond those imposed by the Order on Central Enforcement and the Qualified Protected Order.	х	х	х	х	х			х		х	х	Х	х
H. The subpoena calls for the production of documents protected from disclosure as reflective of attorney-client communications and/or attorney work product.	Х	х	х	х	х	Х	х	х	х		х		х
I. The PSC failed to provide the fee for one day's attendance as required by Rule 45(b)(1).	Х	х	х	х	Х		х	х	х	x			
J. Clinics that are parties should have been served a request for production pursuant to Rule 34 rather than a subpoena pursuant to Rule 35.													
K. The subpoena was improperly served via Federal Express.								Х					
L. The subpoena calls for the production of documents outside the clinic's possession, custody or control.													
M. The subpoena provided only 21 or 30 days to respond, which is not a reasonable amount of time.	Х	Х	х	х	х			х			х	Х	
N. Rule 45(b)(1) requires that subpoenas be served on each party to the MDL. Comments to the Rule say that parties should have given notice before service of the subpoenas on third parties.													

# Coase-11123-mid-082419-F2MS Document 325-2 Filed 07/17/13 Page 450-9156 EXHIBIT B

Objector	Carilion Surgery Center New River Valley	North Carolina Orthopedic Clinic		Surgical Park Center, Ltd.	Kelvas	St. Thomas Outpatient Neurological Center			Surgery Center of Wilson, LLC		Neuromuscular and Rehabilitation Associates of Northern Michigan
II. JURISDICTIONAL AND PROCEDURAL OBJECTIONS											
E. This court does not have jurisdiction to enforce the subpoena.					Х	х		х			
F. The clinic is not a party to any litigation and/or has no injured patients.			х	х							х
G. The subpoena imposes burdens other than or beyond those imposed by the Order on Central Enforcement and the Qualified Protected Order.	х	х	х	Х	х	х		x	Х		х
H. The subpoena calls for the production of documents protected from disclosure as reflective of attorney-client communications and/or attorney work product.	Х		Х	Х	х	Х	х	x	x		х
I. The PSC failed to provide the fee for one day's attendance as required by Rule 45(b)(1).		Х	х	х	х	х	Х		х		
J. Clinics that are parties should have been served a request for production pursuant to Rule 34 rather than a subpoena pursuant to Rule 35.											
K. The subpoena was improperly served via Federal Express.											
L. The subpoena calls for the production of documents outside the clinic's possession, custody or control.			х	Х							
M. The subpoena provided only 21 or 30 days to respond, which is not a reasonable amount of time.		Х				Х		Х	Х		х
N. Rule 45(b)(1) requires that subpoenas be served on each party to the MDL. Comments to the Rule say that parties should have given notice before service of the subpoenas on third parties.					Х	х		x		х	х

# Coase-11:123-mid-08:2419-F1-105 Document 3:25-2 Filed 07/19/13 Page 67-09/156 EXHIBIT B

	Pachastar Prain	Incight Hoalth	Inchira Haalth	Dain	Dr. O'Connell's	Groonspring	Dain
	Rochester Brain	Insight Health	Inspira Health	Pain			Pain
	and Spine	Corp.	Network, Inc. and	Associates of	Pain Care	Surgery Center	
Objector	Neurosurgery &		Inspira Medical	Charleston	Center		West Florida
	Pain		Center, Inc.				
II. JURISDICTIONAL AND PROCEDURAL							
OBJECTIONS							
OBJECTIONS							
E. This court does not have jurisdiction to enforce							
the subpoena.	Х			Х	Х		
F. The clinic is not a party to any litigation and/or							
has no injured patients.	Х						
G. The subpoena imposes burdens other than or							
beyond those imposed by the Order on Central				1			
Enforcement and the Qualified Protected Order.	Х	X			Х	Х	Х
Zamine Transfer of the Control of th							
H. The subpoena calls for the production of							
documents protected from disclosure as							
reflective of attorney-client communications	х						
and/or attorney work product.	^						
and of attorney work product.							
I. The PSC failed to provide the fee for one day's							
attendance as required by Rule 45(b)(1).	Х					х	х
	^					,	^
J. Clinics that are parties should have been							
served a request for production pursuant to Rule			x				
34 rather than a subpoena pursuant to Rule 35.			^				
K. The subpoena was improperly served via							
Federal Express.	Х		Х	Х		Х	
L. The subpoena calls for the production of		<u> </u>		1			
documents outside the clinic's possession,				1			
custody or control.							
M. The subpoena provided only 21 or 30 days to							
respond, which is not a reasonable amount of	Х	х	х		х		x
time.	,						
N. Rule 45(b)(1) requires that subpoenas be							
served on each party to the MDL. Comments to				1			
the Rule say that parties should have given notice				1			
before service of the subpoenas on third parties.				1			
· · ·							

# Coase-11123-mid-082419-F2-105 Document 325-2 Filed 07/19/13 Page 48-09/156 EXHIBIT B

Objector	Group of	St. Thomas Outpatient Neurological Center		Howell Allen Clinic, PLLC	Dr. Donald Jones	Liberty Industries, Inc. & Mot. in Support thereof	Southeast Michigan Surgial Hospital	Michigan Pain Specialists		Systems, Inc.	Surgery Center Associates of High Point, LLC	Orthopedic	Baltimore Pain Management Center
III. CONFIDENTIALITY OBJECTIONS													
O. The subpoena calls for the production of confidential or proprietary business information.	х	х	х	х	х				х		х		
P. The subpoena calls for the production of documents protected from disclosure under the doctor-patient privilege, and/or the production of which would violate the requirements of HIPAA and its related regulations.									х	х			

# Coase-11123-mid-082419-F2MS Document 325-2 Filed 07/17/13 Page 89-09/156 EXHIBIT B

Objector	River Valley	Carolina Orthopedic	HCA Health Services of Tennessee (Centennial Medical Center)	Surgical Park Center, Ltd.	Kelvas	St. Thomas Outpatient Neurological Center			Forsyth Street Ambulatory Surgery Center, LLC	Neuromuscular and Rehabilitation Associates of Northern Michigan
III. CONFIDENTIALITY OBJECTIONS										
O. The subpoena calls for the production of confidential or proprietary business information.	х		Х	Х			Х	Х		
P. The subpoena calls for the production of documents protected from disclosure under the doctor-patient privilege, and/or the production of which would violate the requirements of HIPAA and its related regulations.			х	x						х

# Coase-11123-mid-082419-F2105 Document 325-2 Filed 07/17/13 Page 50-09/156 EXHIBIT B

	Rochester Brain	Insight Health	Inspira Health	Pain	Dr. O'Connell's	Greenspring	Pain
	and Spine	Corp.	Network, Inc. and	Associates of	Pain Care	Surgery Center	Consultants of
Objector	Neurosurgery &		Inspira Medical	Charleston	Center		West Florida
	Pain		Center, Inc.				
III. CONFIDENTIALITY OBJECTIONS							
O. The subpoena calls for the production of							
confidential or proprietary business information.	X		X			х	
	^		^			^	
D. The submoons calls for the production of							
P. The subpoena calls for the production of documents protected from disclosure under the							
doctor-patient privilege, and/or the production							
of which would violate the requirements of	Х	Х	Х	Х	Х	Х	Х
HIPAA and its related regulations.							

# Case 1:13-md-02419-FDS Document 373-2 Filed 07/17/13 Page 10 of 12 EXHIBIT B

Objector	Group of	St. Thomas Outpatient Neurological Center	Surgery Center, PLLC	Howell Allen Clinic, PLLC	Jones	Inc. & Mot. in Support thereof	•	Systems, Inc.	Surgery Center Associates of High Point, LLC	Orthopedic	Baltimore Pain Management Center
IV. MOTIVE OBJECTIONS											
Q. The PSC's subpoenas are thinly-veiled attempts to identify new clients.								х			

# Case 1:13-md-02419-FDS Document 373-2 Filed 07/17/13 Page 51 of 52 EXHIBIT B

0		Carolina Orthopedic	(Centennial Medical	Surgical Park Center, Ltd.	Kelvas		•	Ambulatory Surgery	Neuromuscular and Rehabilitation Associates of Northern Michigan
_	MOTIVE ODJECTIONS	Clinic	Center)			Center			
11	. MOTIVE OBJECTIONS								
	The PSC's subpoenas are thinly-veiled tempts to identify new clients.		х	х					

# Case 1:13-md-02419-FDS Document 373-2 Filed 07/17/13 Page 52 of 52 exhibit B

Objector	·	Network, Inc. and	Associates of	Dr. O'Connell's Pain Care Center	Surgery Center	Pain Consultants of West Florida
IV. MOTIVE OBJECTIONS						
Q. The PSC's subpoenas are thinly-veiled attempts to identify new clients.						х

#### **EXHIBIT C**

#### Exhibit \_\_\_ to Subpoena

Deleted: A

<u>Unless otherwise noted, all requests pertain to the time period October 6, 2010 through October 6, 2012</u>

1. <u>MPA and Triamcinolone:</u> Any and all documents and/or electronically stored information ("ESI") reflecting, and/or related in any way whatsoever to, the procurement of methylprednisolone acetate ("MPA") and <u>Triamcinolone</u> from New England Compounding Pharmacy, Inc. ("NECP") that the CDC has identified as contaminated including without limitation of the foregoing, information reflecting dates of shipment and/or receipt, quantities of shipment, lot numbers and other identifying labels, sizes of containers of steroid preparation, the cost you paid for the steroid preparation, applicable warranties, shelf life, expiration dates, requirements and instructions for shipment and/or storage, and the specific identity of the preparation being purchased. Also including account information, prescriptions submitted to NECP, prescription order forms, NECP charges for MPA (before and after any discounts applied) or any other compounded steroid medication encompassed by this request.

**Deleted:** any other injectable steroid preparations compounded steroid medication

**Deleted:** during the two-year period immediately preceding October 6, 2012,

Deleted:

2. <u>Equivalents to MPA and Triamcinolone:</u> Any and all documents and/or ESI reflecting, and/or related in any way whatsoever to, the procurement of <u>any equivalent medication to MPA or Triamcinolone</u>, or its generic or name-brand equivalent, <u>or any other NECC compounded medication identified as contaminated by the CDC</u>, from any producer, compounding facility or manufacturer other than NECP, <u>since 1/1/2012</u>, including without limitation of the foregoing, information reflecting dates of shipment and/or receipt, quantities of shipment, lot numbers and other identifying labels, sizes of containers of the product, the cost you paid for the product, applicable warranties, shelf life, expiration dates, requirements and instructions for shipment and/or storage, and the specific identity of the preparation being purchased.

Deleted: since October 6, 2007

3. <u>Cardioplegic solution:</u> Any and all documents and/or ESI reflecting, and/or related in any way whatsoever to, the procurement of cardioplegic solution from NECP that the CDC has identified as contaminated including without limitation of the foregoing, information reflecting dates of shipment and/or receipt, quantities of shipment, lot numbers and other identifying labels, sizes of containers of cardioplegic solution, the cost you paid for the cardioplegic solution, applicable warranties, shelf life, expiration dates, and requirements and instructions for shipment and/or storage. Also including prescriptions submitted to NECP, prescription order forms, NECP charges for cardioplegic solution (before and after any discounts applied).

**Deleted:** during the two-year period immediately preceding October 6, 2012,

4. <u>Betamethasone:</u> Any and all documents and/or ESI reflecting, and/or related in any way whatsoever to, the procurement of <u>Betamethasone</u> from NECP that the <u>CDC</u> has identified as contaminated, including without limitation of the foregoing, information reflecting dates of shipment and/or receipt, quantities of shipment, lot numbers and other identifying labels, sizes of containers of ophthalmic solution, the cost you paid for the ophthalmic solution, applicable warranties, shelf life, expiration dates, and requirements and instructions for shipment

Deleted: ophthalmic

Deleted: solution

**Deleted:** during the two-year period immediately preceding October 6, 2012

#### **EXHIBIT C**

and/or storage. Also including prescriptions submitted to NECP, prescription order forms, NECP charges for opthalmic solution (before and after any discounts applied).

5.

- 6. <u>Identification of exposed patients:</u> Any and all documents and/or ESI reflecting, and/or related to, the identification of each and every patient that was administered an NECP product that the CDC has identified as contaminated, or that have previously been compiled in response to a request from the Centers for Disease Control and Prevention, the Federal Food and Drug Administration, and/or any other Federal, state or local regulatory agency, any Grand Jury Subpoena, or any other governmental entity, including patient name, address, date of birth, identification of product administered, and date product was administered.
- 7. <u>Communications with NECP:</u> Any and all documents and/or ESI reflecting or containing communications (written or otherwise) between <u>NAME OF TARGET HEALTHCARE PROVIDER</u> ("Healthcare Provider"), its employees, principals, partners, and/or agents, and NECP, its employees and/or agents, during the two-year period immediately preceding October 6, 2012, including, but not limited to, any complaints or adverse event reports made to NECP by the Healthcare Provider.
- 8. <u>Information about NECP's qualifications:</u> Any and all documents and/or ESI reflecting or containing information obtained by the Healthcare Provider, its employees and/or agents, regarding NECP, including without limitation of the foregoing, NECP's qualifications, certifications or accreditations, or lack thereof, regulatory compliance, lack of regulatory compliance, operations, enforcement actions, suitability for conducting its business, legal actions and/or warnings, brochures, policies and procedures, ordering and delivery information company overviews, standard operating procedures, executive summaries, attachments A, B or others (relating to HIPAA, NECP policies and procedures, or other information).
- 9. <u>Communications received about fitness of NECP's products:</u> Any and all documents and/or ESI reflecting or containing information obtained by, or communications received by, the Healthcare Provider, its employees and/or agents, concerning the fitness of any products purchased or obtained from NECP for their intended use, <u>for the medical products determined by the CDC to be contaminated</u>, including but not limited to any environmental testing results, microbiology reports or certificates of analysis.
- 10. <u>Information received from governmental entities:</u> Any and all documents and/or ESI reflecting or containing information obtained by, or sent to, the Healthcare Provider, its employees and/agents, from the Centers for Disease Control and Prevention, the Federal Food and Drug Administration, and/or any other Federal, state or local regulatory agency, concerning the fitness of any products manufactured, compounded or produced by NECP for their intended purpose.
- 42. <u>Marketing information:</u> Any and all documents and/or ESI reflecting or containing marketing information from NECP, NECP's agents, or any sales company or person marketing, selling, or attempting to sell products on behalf of NECP.

Deleted: Any and all documents and/or ESI reflecting, and/or related in any way whatsoever to, the procurement of preservative-free saline solution from NECP that the CDC has identified as contaminated during the two-year period immediately preceding October 6, 2012, including without limitation of the foregoing, information reflecting dates of shipment and/or receipt, quantities of shipment, lot numbers and other identifying labels, sizes of containers of saline solution, the cost you paid for the saline solution, applicable warranties, shelf life, expiration dates, and requirement and instructions for shipment and/or storage. Also including prescriptions submitted to NECP, prescription order forms, NECP charges for preservative-free saline solution (before and after any discounts applied).

**Deleted:** during the two-year period immediately preceding October 6, 2012,

**Deleted:** during the two-year period immediately preceding October 6, 2012

Deleted: medications

Deleted: 11. Any and all documents and/or ESI reflecting or containing communications between the Healthcare Provider and any federal or state agency (including, but not limited to state licensing authorities, the Food and Drug Administration, and the Centers for Disease Control and Prevention) in connection with the procurement of products from any compounding pharmacy.¶

#### **EXHIBIT C**

- 13. <u>Contracts with NECP:</u> Any and all documents and/or ESI reflecting or containing agreements, contracts and/or warranties between the Healthcare Provider and NECP, NECP's agents, or any sales company or person marketing, selling, or attempting to sell products on behalf of NECP.
- 14. <u>Recall notices received:</u> Any and all documents and/or ESI reflecting or containing recall notices received by the Healthcare Provider pertaining to products produced by NECP, including without limitation of the foregoing, the date, time and manner of receipt of the recall notices, the specific person or persons within the Healthcare Provider who received the notice, and the substance of the notice.
- 15. <u>Communications responding to recall notices:</u> Any and all documents and/or ESI reflecting or containing communications made or issued by the Healthcare Provider, its employees and/or agents, in response to any recall notice regarding NECP products, including without limitation of the foregoing, the date, time and manner of transmission of the communication, the person(s) to which the communication was directed, and the person at the Healthcare Provider who made or delivered the communication.
- 16. <u>Compliance with USP:</u> Any and all documents regarding any investigation or inquiry the Healthcare Provider performed related to attempts by NECP to comply with United States Pharmacopeia National Formulary, Chapter 797 (USP NF General Chapter 797, entitled "Pharmaceutical Compounding Sterile Preparations").
- 17. <u>Insurance policies:</u> Any and all policies of insurance, including without limitation of the foregoing, professional liability, malpractice, products liability, general liability, and comprehensive or umbrella policies, issued to the Healthcare Provider and/or its principal officers and directors and/or any physician working for or on behalf of the Healthcare Provider, for the policy periods <u>covering any use of NECP medical products identified as contaminated by the CDC</u>.

18. <u>Articles of incorporation:</u> Articles of Incorporation and/or By-Laws applicable to the Healthcare Provider for calendar years 2011, 2012 and 2013.

**Deleted:** including calendar years 2011, 2012 and 2013

Deleted: . 19. . Any and all documents and/or ESI reflecting or containing the names, addresses and positions (President, Vice-President, Director, etc.) within the Healthcare Provider of all officers and directors of the Healthcare Provider during the calendar years 2011, 2012 and 2013.¶

- . 20. . Any and all documents showing the entities or individuals with an ownership interest in the Healthcare Provider.¶
- 21. Any and all organizational charts maintained by the Healthcare Provider and/or any documents listing directors, officers, employees, and/or agents of the Healthcare Provider showing the names and positions of said directors, officers, employees, and/or agents and their relationship or rank within the Healthcare Provider. ¶